571 related articles for article (PubMed ID: 30028961)
21. Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.
Krawczyk N; Meier-Stiegen F; Banys M; Neubauer H; Ruckhaeberle E; Fehm T
Biomed Res Int; 2014; 2014():415721. PubMed ID: 24895575
[TBL] [Abstract][Full Text] [Related]
22. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer.
Liu DG; Xue L; Li J; Yang Q; Peng JZ
Cancer Biomark; 2018; 22(3):417-426. PubMed ID: 29758927
[TBL] [Abstract][Full Text] [Related]
23. Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC.
Wang ZL; Zhang P; Li HC; Yang XJ; Zhang YP; Li ZL; Xue L; Xue YQ; Li HL; Chen Q; Chong T
Cancer Biol Ther; 2019; 20(4):505-512. PubMed ID: 30359544
[TBL] [Abstract][Full Text] [Related]
24. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis.
Yokobori T; Iinuma H; Shimamura T; Imoto S; Sugimachi K; Ishii H; Iwatsuki M; Ota D; Ohkuma M; Iwaya T; Nishida N; Kogo R; Sudo T; Tanaka F; Shibata K; Toh H; Sato T; Barnard GF; Fukagawa T; Yamamoto S; Nakanishi H; Sasaki S; Miyano S; Watanabe T; Kuwano H; Mimori K; Pantel K; Mori M
Cancer Res; 2013 Apr; 73(7):2059-69. PubMed ID: 23378342
[TBL] [Abstract][Full Text] [Related]
25. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
[TBL] [Abstract][Full Text] [Related]
26. The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells.
Liu H; Zhang X; Li J; Sun B; Qian H; Yin Z
J Cancer Res Clin Oncol; 2015 Feb; 141(2):189-201. PubMed ID: 24965746
[TBL] [Abstract][Full Text] [Related]
27. Circulating Tumor Cells.
García SA; Weitz J; Schölch S
Methods Mol Biol; 2018; 1692():213-219. PubMed ID: 28986899
[TBL] [Abstract][Full Text] [Related]
28. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
[TBL] [Abstract][Full Text] [Related]
29. Evidence for circulating cancer stem-like cells and epithelial-mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy.
Mirza S; Jain N; Rawal R
Tumour Biol; 2017 Mar; 39(3):1010428317695915. PubMed ID: 28347243
[TBL] [Abstract][Full Text] [Related]
30. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
31. Epithelial-Mesenchymal Transition Status of Circulating Tumor Cells Is Associated With Tumor Relapse in Head and Neck Squamous Cell Carcinoma.
Tada H; Takahashi H; Ida S; Nagata Y; Chikamatsu K
Anticancer Res; 2020 Jun; 40(6):3559-3564. PubMed ID: 32487658
[TBL] [Abstract][Full Text] [Related]
32. Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma.
Ou H; Huang Y; Xiang L; Chen Z; Fang Y; Lin Y; Cui Z; Yu S; Li X; Yang D
Dig Dis Sci; 2018 Sep; 63(9):2373-2380. PubMed ID: 29926241
[TBL] [Abstract][Full Text] [Related]
33. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells.
Książkiewicz M; Markiewicz A; Zaczek AJ
Pathobiology; 2012; 79(4):195-208. PubMed ID: 22488297
[TBL] [Abstract][Full Text] [Related]
34. The biology and clinical potential of circulating tumor cells.
Lozar T; Gersak K; Cemazar M; Kuhar CG; Jesenko T
Radiol Oncol; 2019 May; 53(2):131-147. PubMed ID: 31104002
[TBL] [Abstract][Full Text] [Related]
35. Clinical Relevance of a Candidate Stem Cell Marker, p75 Neurotrophin Receptor (p75NTR) Expression in Circulating Tumor Cells.
Okumura T; Yamaguchi T; Watanabe T; Nagata T; Shimada Y
Adv Exp Med Biol; 2017; 994():247-254. PubMed ID: 28560678
[TBL] [Abstract][Full Text] [Related]
36. Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer.
Chen J; Ye C; Dong J; Cao S; Hu Y; Situ B; Xi X; Qin S; Xu J; Cai Z; Zheng L; Wang Q
J Transl Med; 2020 Feb; 18(1):59. PubMed ID: 32028979
[TBL] [Abstract][Full Text] [Related]
37. Fluid shear stress induces cancer stem cell-like phenotype in MCF7 breast cancer cell line without inducing epithelial to mesenchymal transition.
Triantafillu UL; Park S; Klaassen NL; Raddatz AD; Kim Y
Int J Oncol; 2017 Mar; 50(3):993-1001. PubMed ID: 28197635
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.
Li TT; Liu H; Li FP; Hu YF; Mou TY; Lin T; Yu J; Zheng L; Li GX
World J Gastroenterol; 2015 Dec; 21(47):13259-67. PubMed ID: 26715808
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.
Mentis AA; Grivas PD; Dardiotis E; Romas NA; Papavassiliou AG
Cell Mol Life Sci; 2020 Sep; 77(18):3671-3690. PubMed ID: 32333084
[TBL] [Abstract][Full Text] [Related]
40. Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition.
Yang J; Ma J; Jin Y; Cheng S; Huang S; Zhang N; Wang Y
Sci Rep; 2021 Mar; 11(1):6540. PubMed ID: 33753862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
